UC Irvine

UC Irvine Previously Published Works

Title

Body mass index and mortality in heart failure: a meta-analysis.

Permalink

<https://escholarship.org/uc/item/84z6x7fs>

Journal

American heart journal, 156(1)

ISSN

0002-8703

Authors

Oreopoulos, Antigone
Padwal, Raj
Kalantar-Zadeh, Kamyar
et al.

Publication Date

2008-07-01

DOI

10.1016/j.ahj.2008.02.014

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Body mass index and mortality in heart failure: A meta-analysis

Antigone Oreopoulos, MSc,^a Raj Padwal, MD, MSc,^b Kamyar Kalantar-Zadeh, MD, MPH, PhD,^c Gregg C. Fonarow, MD, FACC,^d Colleen M. Norris, PhD,^c and Finlay A. McAlister, MD, MSc^b
Alberta, Canada; Torrance, and Los Angeles, CA

Background In patients with chronic heart failure (CHF), previous studies have reported reduced mortality rates in patients with increased body mass index (BMI). The potentially protective effect of increased BMI in CHF has been termed the *obesity paradox* or *reverse epidemiology*. This meta-analysis was conducted to examine the relationship between increased BMI and mortality in patients with CHF.

Methods We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Scopus, and Web of Science to identify studies with contemporaneous control groups (cohort, case-control, or randomized controlled trials) that examined the effect of obesity on all-cause and cardiovascular mortality. Two reviewers independently assessed studies for inclusion and performed data extraction.

Results Nine observational studies met final inclusion criteria (total n = 28,209). Mean length of follow-up was 2.7 years. Compared to individuals without elevated BMI levels, both overweight (BMI ~25.0-29.9 kg/m², RR 0.84, 95% CI 0.79-0.90) and obesity (BMI ≥30 kg/m², RR 0.67, 95% CI 0.62-0.73) were associated with lower all-cause mortality. Overweight (RR 0.81, 95% CI 0.72-0.92) and obesity (RR 0.60, 95% CI 0.53-0.69) were also associated with lower cardiovascular mortality. In a risk-adjusted sensitivity analysis, both obesity (adjusted HR 0.88, 95% CI 0.83-0.93) and overweight (adjusted HR 0.93, 95% CI 0.89-0.97) remained protective against mortality.

Conclusions Overweight and obesity were associated with lower all-cause and cardiovascular mortality rates in patients with CHF and were not associated with increased mortality in any study. There is a need for prospective studies to elucidate mechanisms for this relationship. (Am Heart J 2008;156:13-22.)

Obesity is an independent risk factor for cardiovascular morbidity and mortality and doubles the risk of developing heart failure (HF).¹ However, the prognostic significance of obesity in the setting of established HF is not clear. Observational data suggest a protective effect of

obesity, which has been termed the *obesity paradox* or *reverse epidemiology*.² In addition, although wasting (cachexia) appears to be a poor prognostic factor in HF,³ small observational studies have demonstrated improvements in left ventricular function and symptoms in patients with HF after intentional weight loss.^{4,5}

Although the updated 2008 Canadian Cardiovascular Society (CCS) Census Conference guidelines for the treatment and management of HF refer to the obesity paradox, they continue to recommend weight loss for obese patients with HF,⁶ even though this recommendation is not supported by evidence from clinical trials. To comprehensively synthesize the evidence pertaining to this issue, we undertook this systematic review to examine the association between increased BMI and mortality in patients with chronic HF (CHF).

Methods

Search strategy

Detailed search strategies were designed with the help of a research librarian to identify randomized control trials (RCTs) and observational studies examining the effect of overweight and obesity on total mortality in CHF. The Cochrane Central

From the ^aDepartment of Clinical Epidemiology, School of Public Health, University of Alberta, Edmonton, Alberta, Canada, ^bDivision of General Internal Medicine, University of Alberta, Edmonton, Alberta, Canada, ^cDivision of Nephrology and Hypertension, Harbor-UCLA Medical Center, Torrance, CA, ^dDivision of Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA, and ^eFaculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.

There was no project specific funding, but A.O. is supported by a CIHR Strategic Training Fellowship in Tomorrow's Research Cardiovascular Health Professionals; C.M.N. is supported by career salary awards from the Alberta Heritage Foundation for Medical Research; C.M.N. is also supported by New Investigator Awards from the Canadian Institutes of Health Research; G.C.F. is supported by a grant from the National Heart Lung and Blood Institute and the Eliot Corday Foundation; K.K. is supported by a grant from the National Institute of Diabetes, Digestive and Kidney Disease from the NIH and by a Grant-in-Aid from the American Heart Association; and F.A.M. is supported by career salary awards from AHFMR and CIHR as well as the Patient Health Management Chair at the University of Alberta.

Submitted November 5, 2007; accepted February 14, 2008.

Reprint requests: Raj Padwal, MD, MSc, Division of General Internal Medicine, University of Alberta, 2E3.22 Walter C. Mackenzie Health Sciences Center, 8440-112 Street, Edmonton, Alberta, Canada T6G 2B7.

E-mail: rpadwal@ualberta.ca

0002-8703/\$ - see front matter

© 2008, Mosby, Inc. All rights reserved.

doi:10.1016/j.ahj.2008.02.014

Register of Controlled Trials (1990-June 2007), MEDLINE (1966-June 2007), EMBASE (1988-June 2007), Scopus (1966-June 2007) and Web of Science (1900-June 2007) were searched, reference lists of primary studies and review articles were scanned, and 3 experts in the field were contacted. No language or age restrictions were applied. Databases were searched using “heart failure” or “cardiac failure” and “obes\$” or “body mass index” as key words, text words or MESH headings in combination with “mortality,” “survival,” “reverse epidemiology,” and “obesity paradox.”

Inclusion and exclusion criteria

Studies were included if they reported mortality in HF patients according to BMI category. The traditional World Health Organization (WHO)/National Institutes of Health (NIH) body mass index (BMI) classification scheme uses $<18.5 \text{ kg/m}^2$, $18.5\text{--}24.9 \text{ kg/m}^2$, $25.0\text{--}29.9 \text{ kg/m}^2$, and $\geq 30 \text{ kg/m}^2$ to define underweight, normal BMI, overweight, and obesity, respectively.⁷ However, the lower cut point for normal is controversial and is sometimes cited as 22.5 kg/m^2 .⁸ We anticipated that not all studies would use the WHO/NIH BMI classification scheme; therefore, in order to avoid eliminating studies with important information, we considered BMI levels within 2 kg/m^2 of standard categories to be acceptable. In some instances, we collapsed the reported BMI categories into ones that most closely approximated standard WHO/NIH categories. Whenever possible, we used BMI levels of approximately 18.5 to 24.9 kg/m^2 , defined as “normal” BMI, as the control group. If it was not possible to extract data for this BMI range for a given study, we used a BMI of $<25.0 \text{ kg/m}^2$, defined as “nonelevated” BMI, as the control. Similarly, we defined “underweight” as BMI of approximately $<18.5 \text{ kg/m}^2$; however, studies including patients with normal BMI levels of $<23.0 \text{ kg/m}^2$ were defined as “underweight/low-normal.” Studies comparing obese vs nonobese (ie, normal plus overweight vs obese) were excluded unless outcomes in the normal BMI population alone could be ascertained.

Outcomes

The primary outcome was all-cause mortality, with a secondary outcome of cardiovascular mortality. When studies reported mortality at ≥ 2 time intervals, the longest follow-up period was used for analysis.

Trial selection and data extraction

Two reviewers (A.O. and R.P.) independently reviewed the results of the literature search and independently performed data extraction. Cohen κ coefficients were calculated to assess inter-observer agreement for study inclusion and data extraction. Disagreements were resolved through consensus. Reviewers were not blinded to the authors' names and institutions, journal of publication, or study results. When necessary, additional data were requested from the primary study authors. Study quality was assessed using the Ottawa-Newcastle Assessment Scale for observational studies.⁹ Maximum score on this scale is a total of 9. “Good” was defined as a total score of 7 to 9; “fair,” a total score of 4–6; and “poor,” defined as a total score of <4 .

Data analysis

Primary analysis. Unadjusted all-cause and cardiovascular mortality data were extracted and pooled to calculate relative risks (RR) and 95% CI with RevMan (version 4.2.8 for

Figure 1

QUOROM (Quality Of Reporting Of Meta-analyses) statement flow diagram.

Windows; Oxford, The Cochrane Collaboration, 2003) using a random effects model. A priori, we suspected that some studies might group underweight and normal weight patients into one category. This may introduce bias, as being underweight or cachectic are known to be associated with a poorer prognosis in patients with HF and other chronic diseases.⁵ Therefore, we conducted a sensitivity analysis in which we repeated our primary analysis after excluding these studies.^{10–12}

Secondary analyses. As secondary analyses, we examined total mortality in patients with moderate to severe obesity ($\text{BMI} \geq 35 \text{ kg/m}^2$) and underweight/low-normal-weight ($\text{BMI} < 23.0 \text{ kg/m}^2$), comparing these groups to patients with nonelevated and normal BMI levels, respectively. We also performed a baseline risk-adjusted analysis to determine if our main results were robust when quantitative pooling was limited to those studies in which we could calculate pooled adjusted all-cause mortality hazard ratios (HR). This was done because some studies have shown obesity to be associated with favourable characteristics such as younger age, higher left ventricular ejection fraction, and higher systolic blood pressure,¹³ and the presence of these favourable characteristics may potentially explain the obesity paradox.

Data pooling and heterogeneity

The generic inverse variance method was used to pool the data (log hazards and SE) using a random effects model. Heterogeneity was examined using the Higgins I^2 test.¹⁴

Table 1. Studies evaluating the effect of obesity on all-cause mortality in HF

Study, y	Population	NYHA class	Sample size	Mean age, % female	BMI categories reported (kg/m ²)	Ottawa-Newcastle Quality Assessment Score (max total 9)	Mean follow-up
Bozkurt et al, ¹⁵ 2005 (USA)	Post hoc analysis of the DIG database	I-IV	7788	63, 24%	Normal 18.5-24.9, overweight 25.0-29.9, obese ≥30	8	3
Butler et al, ¹⁸ 2005 (USA)	Post hoc analysis of 2 FDA-approved clinical trials for LVAD placement	IV	222	51, 13%	Underweight/low-normal <23.0, normal 23.0-26.3, overweight 26.4-29.4, Obese ≥29.4	8	1
Cicoira et al, ¹⁷ 2007 (Italy)	Post hoc analysis of the Val-HeFT Study	II-IV	4463	63, 18%	Underweight/low-normal <22.0, normal 22.0-24.9, overweight 25.0-29.9, Obese ≥30	9	1
Davos et al, ¹² 2003 (UK)	Retrospective, single-center cohort; NYHA class I-IV	I-IV	525	61, 17%	Nonelevated BMI <25.0, overweight ~25.0-29.0, obese ≥29-34.0, moderately/severely obese ≥34.0	9	3
Gustafsson et al, ¹⁶ 2005 (Denmark)	Post hoc analysis of the DIAMOND-CHF study	III-IV	4504	72, 39%	Underweight <18.5, normal 18.5-24.9, overweight 25.0-29.9, obese ≥30	9	6
Kenchiah et al, ¹³ 2007 (USA)	Post hoc analysis of the CHARM study	II-IV	7599	66, 32%	Underweight/low-normal <22.5, normal 22.5-24.9, overweight 25.0-29.9, obese 30.0-34.9, moderately/severely obese ≥35.0	9	3
Hall et al, ¹⁰ 2005 (USA)	Retrospective, 20-hospital integrated health care system; NYHA class not given	Not given	2707	Age and sex not reported	Nonelevated BMI <24.3, overweight 24.4-28.5, obese 28.6-34.1, moderately/severely obese ≥34.2	8	3
Kristorp et al, ¹¹ 2005 (Denmark)	Prospective, single-center	I-III (1 patient had IV)	195	69, 28%	Nonelevated BMI <25, overweight 25-29.9, obese ≥30	9	2.5
Lavie et al, ¹⁹ 2003 (USA)	Retrospective, single-center cohort	I-III	206	54, 19%	Normal 18.5-24.9, overweight 25.0-29.9, obese ≥30	8	1.5

DIG, Digitalis Investigation Group; FDA, Food and Drug Administration; LVAD, Left ventricular assist device; DIAMOND, Danish Investigations of Arrhythmia and Mortality.

Higgins I^2 values of 25%, 50%, and 75% can be interpreted as indicating low, moderate, and high heterogeneity.

Results

Of the 521 initial citations, 9 met our study eligibility criteria (Figure 1): 5 post hoc analyses of randomized controlled trial (RCT) study populations^{13,15-18} (all evaluated medication or device therapies in CHF and were not conducted to examine the issue of BMI and outcomes), 1 prospective cohort study in which the primary study question was the association between BMI and outcomes in CHF,¹¹ and 3 retrospective analyses of cohort data collected for another research question^{10,12,19} (Table 1) (total n = 28 209). Interobserver agreement was 1.0 for study inclusion and 0.8 for data extraction.

We found no RCTs that examined mortality outcomes after intentional weight loss in obese patients with HF. Six

studies were excluded because the reported BMI was in an unusable format (either used BMI as a continuous variable or BMI categories with ranges that were too different from the WHO/NIH ranges); none found obesity or overweight to be a significant predictor of increased mortality.²⁰⁻²⁵ All studies were of high methodological quality (score 8-9/9) as assessed by the Ottawa-Newcastle criteria. Mean length of follow-up was 2.7 years.

Primary analysis

Compared to individuals without elevated BMI levels, both overweight (RR 0.84, 95% CI 0.79-0.90) (Figure 2) and obesity (RR 0.67, 95% CI 0.62-0.73) (Figure 3) were associated with lower all-cause mortality. Compared to patients with normal BMI levels, overweight (RR 0.81; 95% CI 0.72-0.92) and obesity (RR 0.60, 95% CI 0.53-0.69) were also associated with lower cardiovascular

Figure 2 **Figure 3**

mortality, whereas underweight/low-normal-weight was associated with higher cardiovascular mortality (RR 1.20, 95% CI 1.04-1.38) (Figure 4). As 86% of patients in the Butler study¹⁸ had a left ventricular assist device as a bridge to transplant, we conducted a sensitivity analysis excluding this study yielding nearly identical results (data not shown).

Secondary analyses

Of the 9 included studies, 8 included additional data beyond that of obese and normal BMI groups: 3^{10,12,13} reported a moderate-severely obese category, and 4^{13,16-18} reported an underweight or underweight/low-normal-weight category. Compared to patients with nonelevated BMI, moderate-severe obesity was associated with a

Figure 4

lower risk of all-cause mortality (RR 0.62, 95% CI 0.55-0.69) (Figure 5), whereas underweight/low-normal BMI was associated with a significant increase in all-cause mortality (RR 1.25, 95% CI 1.19-1.31) (Figure 5), compared to patients with normal BMI.

Four studies were included in the combined risk-adjusted analysis^{10,13,15,17} (Figure 6). These studies used a Cox proportional hazards regression model to adjust for known baseline differences between study arms. All studies adjusted for age, sex, and New York Heart Association (NYHA) class/severity of CHF. Other covariates adjusted for included race,¹⁵ hypertension,¹⁵ cardiopulmonary ratio,¹⁵ bilirubin,¹⁷ anaemia,¹⁷ C-reactive protein,¹⁷ brain natriuretic peptide,¹⁷ current angina¹⁵ ejection fraction,^{13,15,17} diabetes,^{13,15,17} serum creatinine,^{15,17} etiology of HF,^{15,17} presence of arrhythmia,^{13,17} duration of HF,^{13,15} current smoking,¹³ previous hospitalization for HF,¹³ medications,^{15,17} previous myocardial infarction,^{13,15} heart rate,^{13,15} blood pressure,^{13,15,17} clinical signs/symptoms of CHF,^{13,15,17} and study treatment.^{13,15,17} Compared to patients with nonelevated BMI, obesity and overweight were both associated with a lower risk of adjusted all-cause mortality (adjusted HR

0.88, 95% CI 0.83-0.93 and adjusted HR 0.93, 95% CI 0.89-0.97, respectively). Compared with normal BMI patients, underweight/low-normal-weight patients had a significantly higher risk-adjusted mortality (adjusted HR 1.11; 95% CI 1.01-1.23), whereas obesity significantly reduced the adjusted risk of death when compared with underweight/low-normal-weight CHF patients (adjusted HR 0.79, 95% CI 0.75-0.84). Neither the moderate-severe obesity category nor the cardiovascular mortality end point could be examined in the risk-adjusted analysis due to lack of data. Figure 7 displays a graphic summary of the differences between unadjusted and adjusted results. Although adjusting for baseline variables moved the HRs toward 1, the results of the risk-adjusted analysis remained statistically significant.

Sensitivity analysis

Exclusion of the 3 studies¹⁰⁻¹² that included underweight individuals in their control groups did not affect the combined results for overweight vs normal BMI (HR 0.84, 95% CI 0.77-0.91) or obese vs normal BMI (HR 0.68, 95% CI 0.62-0.76) all-cause mortality comparisons.

Figure 5

Most studies had a mean length of follow-up between 1 and 3 years, but one study by Gustafsson et al¹⁶ had a length of follow-up of 6 years. A post hoc analysis excluding the Gustafsson paper revealed no appreciable change in the associations we found for all-cause mortality: overweight vs nonelevated BMI HR 0.83 (95% CI 0.79-0.97) and obese vs nonelevated BMI HR 0.66 (95% CI 0.59-0.73).

Discussion

Obese and overweight individuals with CHF exhibited lower unadjusted mortality rates compared to CHF patients with nonelevated BMI levels. Furthermore, even after adjustment for baseline risk, obesity and overweight were still associated with lower risk of mortality, and none of the identified studies reported that obesity or overweight were associated with increased mortality. In addition, the 5 studies²⁰⁻²⁴ that analyzed BMI as a continuous variable (excluded from our review) found a significant inverse relationship between increasing BMI and mortality in multivariable analyses. Although our results demonstrate an inverse relationship between BMI and survival, we could not determine if such a relationship is maintained at extreme BMI (ie, $>50 \text{ kg/m}^2$) levels. To our knowledge, this is the first systematic review on this topic.

Our findings are consistent with evidence in other chronic disease populations demonstrating improved

mortality with higher BMI levels.²⁶ In survivors of myocardial infarction, overweight and obese patients are at lower risk for recurrent events compared with patients of normal BMI.²⁷ A recent meta-analysis examining the effect of BMI on mortality on patients post coronary revascularization²⁸ showed that obese patients have similar or lower short- and long-term mortality rates compared to nonelevated BMI patients. Similarly, a low baseline fat percentage and reduction in fat mass over time in are independently associated with higher mortality in chronic hemodialysis patients.²⁹ Although the specific mechanisms may differ, the identification of an obesity paradox in such diverse clinical situations suggests a commonality that merits further investigation.

The finding of extremely high risk of death in the underweight group (likely representing patients with nonintentional weight loss) is also consistent with previous studies.^{3,30} The higher mortality among these patients is likely due to the presence of low protein and energy intake, malnutrition, and even cachexia that can be observed in advanced HF. Heart transplant recipients who are underweight also have a significantly higher mortality.³¹ These observations support the hypothesis that restoration of normal hemodynamics is not sufficient to improve prognosis of malnourished and cachectic CHF patients.

Several potential explanations for the obesity paradox exist. First, selection bias may be a contributing factor. Patients with obesity may be presenting earlier, with

Figure 6

less severe disease, or may have comorbidities more aggressively recognized and treated. Alternatively, only the “healthiest” of obese patients may be surviving long enough to develop HF. In addition, potential confounders such as smoking (which decreases body weight but increases mortality), unrecognized systemic illness, or unintentional weight loss may potentially account for the paradoxical results. To explore the possibility of selection bias, we determined the relative frequencies of reported baseline risk factors known to affect survival outcomes in patients with CHF (Table II). Patients with obesity were younger, had fewer current smokers and lower incidence of previous myocardial infarction, but a higher prevalence of comorbidities such as hypertension and diabetes mellitus. Other comorbidities such as duration of HF, chronic obstructive pulmonary disease and NYHA class III/IV were similar in patients with obesity compared to those with normal BMI. Use of angiotensin-converting enzyme (ACE) inhibitors and digoxin and ischemic HF were also

Figure 7

Table II. Baseline characteristics of study population according to BMI

	Underweight/low-normal	Normal	Overweight	Obese
Age (y), studies = 6, n = 21 821	69.2	68.7	66.5	62.3
Women (%), studies = 6, n = 25 250	41.5	30.7	22.5	30.6
Duration of HF (mo), studies = 3, n = 19 899	32.7	24.0	28.6	29.1
NYHA class III or IV (%), studies = 4, n = 24 909	54.3	45.9	42.9	47.7
Ischemic heart disease (%), studies = 5, n = 25 434	61.1	64.0	66.4	58.1
Ejection fraction (%), studies = 2, n = 8152	Not reported	30.6	31.9	34.1
COPD (%), studies = 1, n = 4700	35	23	21	24
Diabetes (%), studies = 5, n = 25 131	16.9	18.5	25.2	38.9
Previous MI (%), studies = 2, n = 15 199	53.5	60.4	62.6	50.3
Hypertension (%), studies = 4, n = 20 778	34.8	34.1	42.1	56.5
Systolic blood pressure (mm Hg), studies = 3, n = 15 724	126	126	129	133
Current smoker (%), studies = 3, n = 12 524	25.3	29.2	20.9	18.0
β -Blockers (%), studies = 3, n = 17 282	33.9	29.7	39.6	45.2
Digoxin (%), studies = 2, n = 12 272	54.4	53.3	63.3	47.2
ACE inhibitors (%), studies = 4, n = 24 909	60.4	71.8	70.3	68.4
Diuretics (%), studies = 3, n = 19 899	69.1	76.3	74.1	77.7

COPD, Chronic obstructive pulmonary disease; MI, myocardial infarction.

similar between groups, whereas ejection fraction, systolic blood pressure, and use of β -blockers were higher in the obese group. Although this descriptive analysis is not comprehensive due to the small number of studies included and because other confounders may be affecting survival, these data show that there are both favorable and unfavorable risk factors present in obese patients with CHF. Furthermore, our risk-adjusted analysis suggests a protective effect of overweight and obesity in HF.

It is also possible that excess body weight truly confers a protective effect on HF mortality. Chronic HF is a catabolic state,³² and the development of wasting, characterized by loss of muscle, bone, and fat,³³ is a marker of more severe disease.^{30,34} Studies have demonstrated that many patients with advanced HF are malnourished, with an energy and protein intake that is inadequate to meet their energy requirements.^{35,36} It has been suggested that moderately obese individuals with CHF may have a higher metabolic reserve and may tolerate the metabolic stresses better than lean individuals with CHF.³⁷

Altered cytokine and neuroendocrine profiles of obese patients play a role in modulating HF progression. Tumor necrosis factor α (TNF- α) is elevated in CHF and may contribute to cardiac injury and muscle wasting through its proapoptotic and negative inotropic effects.³⁸ Adipose tissue produces soluble TNF- α receptors³⁹ and may play a cardioprotective role in obese patients by neutralizing the biologic effects of TNF- α . Higher B-type natriuretic peptide (BNP) and N-terminal proBNP levels are also associated with increasing severity of HF and poorer outcomes.⁴⁰ Compared with normal BMI counterparts, overweight and obese patients with acute and chronic HF have lower levels of circulating BNP and NT pro-BNP.⁴¹ Moreover, while increased sympathetic and renin-

angiotensin activity are negative prognostic factors in HF,⁴² a recent study reported attenuated sympathetic nervous system and renin-angiotensin responses to exercise in obese versus lean subjects.⁴³ Alternatively, as obese patients have higher systolic blood pressure, this may permit more aggressive upward titration (or alteration of the pharmacokinetics) of disease-modifying medications including ACE inhibitors and β -blockers; previous reports have suggested that higher blood pressure confers better prognosis in patients with CHF.³⁴ Finally, the interaction between obesity and higher serum lipid levels may also potentially explain the obesity paradox. There is a significant positive correlation between higher cholesterol levels and improved survival in HF.²⁰ The endotoxin-lipoprotein hypothesis states that bacterial lipopolysaccharides are strong stimulators for the release of inflammatory cytokines.⁴⁴ High circulating serum lipoproteins have the ability to bind and detoxify lipopolysaccharides, thereby potentially playing a beneficial role in HF.⁴⁴

Several limitations of this meta-analysis should be noted. First, not all studies reported body weight using the standard WHO/NIH BMI classification system. In particular, 3 studies grouped normal and underweight individuals together. Because underweight, malnutrition, and cachexia are associated with increased mortality in CHF, this may have resulted in an apparent relative benefit of overweight and obesity. It is notable, however, that repeating our analysis after excluding these studies demonstrated nearly identical results. Secondly, as with any systematic review, bias may occur due to selective study publication or if important studies were missed. We searched multiple databases and contacted content experts in an effort to minimize such bias. Third, although BMI is the most commonly used epidemiologic measure of obesity, it is imperfect and does not directly distinguish between adipose and lean tissue or central and peripheral

adiposity. We were unable to determine if the apparent protective effects of obesity are due to increased fat or lean body mass. However, misclassification of body composition using BMI would be expected to bias our relative risks toward the null, thereby potentially masking a nonneutral association between BMI and mortality. Fourth, moderate statistical heterogeneity was found when quantitative pooling was performed for some outcomes. Potential explanations for heterogeneity include between-study differences in temporal and local practice patterns, patient selection, and concomitant therapies. We used a random effects model in an effort to incorporate heterogeneity between trials in our analysis but recognize that this does not eliminate the fact that heterogeneity was present. Finally, the observational nature of the studies identified provides associative, not causal, evidence and mandates caution when interpreting the results.

Conclusions

This systematic review suggests that obese and overweight individuals with CHF are at lower risk for death than CHF patients with normal body weight and we believe there is a need for prospective studies to confirm these findings and elucidate potential mechanisms. Such studies should examine body composition and fat distribution in relation to outcomes in HF and account for intentionality of weight loss and temporal weight change. Studies should also include additional outcomes such as functional status and health-related quality of life to fully explore the relationship between body weight and outcomes in this patient population. Thus, a great deal of further research is required to optimize nutritional/metabolic support for patients with CHF, with the ultimate goal of favorably impacting morbidity and mortality in this patient population.

We thank Ms Jill Hall, Dr Carl Lavie, Dr Michael Lauer, Dr Caroline Kistorp, Dr Tamara Horwich, and Dr Andrew Clark for providing further data regarding their studies.

References

1. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. *N Engl J Med* 2002;347:305-13.
2. Kalantar-Zadeh K, Block G, Horwich T, et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. *J Am Coll Cardiol* 2004;43:1439-44.
3. Anker S, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. *Lancet* 1997;349:1050-3.
4. Mariotti R, Castrogiovanni F, Becherini F, et al. Obesity, weight loss and heart failure. *Eur Heart J* 2004;6(Suppl F):F87-90.
5. Zuber M, Kaeslin T, Studer T, et al. Weight loss of 146 kg with diet and reversal of severe congestive heart failure in a morbidly obese patient. *Am J Cardiol* 1999;84:955-6.
6. Malcom J, Arnold O, Howlett JG, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure—2008 updated: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. *Can J Cardiol* 2008;24:21-40.
7. Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee. *World Health Organization* 1995;854:1-452.
8. Pi-Sunyer FX, Becker DM, Bouchard C, et al. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda (Md): National Institutes of Health in cooperation with the National Heart, Lung, and Blood Institute; 1998 [Publication NIH #98-4083].
9. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. *Ottawa Health Research Institute (OHRI)*; 2006. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Last accessed May 22, 2008.
10. Hall J, French TK, Rasmussen KD, et al. The paradox of obesity in patients with heart failure. *J Am Acad Nurse Prac* 2005;17:542-6.
11. Kristorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. *Circulation* 2005;112:1756-62.
12. Davos C, Downner W, Rauchhaus M, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. *J Cardiac Fail* 2003;9:29-35.
13. Kenchaiah S, Pocock S, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure. Insights from the Candesartan in Heart failure. *Circulation* 2007;116:627-36.
14. Higgins J, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
15. Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. *Am Heart J* 2005;150:1233-9.
16. Gustafsson F, Kragelund CB, Torp-Pedersen C, et al. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. *Eur Heart J* 2005;26:58-64.
17. Ciccoira M, Maggioni A, Latini R, et al. Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial. *Eur J Heart Fail* 2007;9:397-402.
18. Butler J, Howser R, Portner PM, et al. Body mass index and outcomes after left ventricular assist device placement. *Ann Thorac Surg* 2005;79:66-73.
19. Lavie C, Osman A, Milani R, et al. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. *Am J Cardiol* 2003;91:891-4.
20. Horwich T, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. *J Am Coll Cardiol* 2001;38:789-95.
21. Pocock S, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. *Eur Heart J* 2006;27:65-75.
22. Ho K, Keaven MA, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation* 1993;88:107-15.
23. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population. *Eur Heart J* 2001;22:1318-27.
24. Lissin L, Gauri AJ, Froelicher VF, et al. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. *J Cardiac Fail* 2002;8:206-15.
25. Fonarow G, Srikantian P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and in-hospital

- mortality for 108927 patients in the Acute Decompensated Heart Failure National Registry. *Am Heart J* 2007;153:74-81.
26. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Reverse epidemiology: a spurious hypothesis or a hardcore reality? *Blood Purification* 2005;23:57-63.
 27. Ness A, Gunnell D, Hughes J, et al. Height, body mass index, and survival in men with coronary disease: follow up of the Diet and Reinfarction Trial (DART). *J Epidemiol Community Health* 2002; 218-9.
 28. Oreopoulos A, Padwal R, Norris C, et al. Effect of obesity on short- and long-term mortality post coronary revascularization: a meta-analysis. *Obesity* 2007 (In Press).
 29. Kalantar-Zadeh K, Kuwae N, Wu DY, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. *Am J Clin Nutr* 2006;83:202-10.
 30. Anker S, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. *Curr Opin Cardiol* 1999; 14:211-6.
 31. Grady K, Naftel D, Costanzo M, et al. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices. *J Heart Lung Transplant* 1999;18:750-63.
 32. Berry C, Clark AL. Catabolism in chronic heart failure. *Euro Heart J* 2000;21:521-32.
 33. Anker S, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. *Euro Heart J* 1999;20:683-93.
 34. Anker S, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study. *Lancet* 2003;361:1077-83.
 35. Aquilani R, Opasich C, Verri M, et al. Is nutritional intake adequate in chronic heart failure patients? *J Am Coll Cardiol* 2003;42: 1218-23.
 36. Freeman L, Roubenoff R. The nutrition implications of cardiac cachexia. *Nutr Rev* 1994;52:340-7.
 37. Imbearlt P, Tremblay A, Simoneau J, et al. Weight loss-induced rise in plasma pollutant is associated with reduced skeletal muscle oxidative capacity. *Am J Physiol Endocrinol Metab* 2002;282:E574-9.
 38. Feldman A, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. *J Am Coll Cardiol* 2000;35:537-44.
 39. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. *Am J Physiol* 1999;277:E971-5.
 40. Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. *J Am Coll Cardiol* 2001;38:1934-41.
 41. Horwich T, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. *J Am Coll Cardiol* 2006;47:85-90.
 42. Schrier R, Abraham WT. Hormones and hemodynamics in heart failure. *N Eng J Med* 1999;341:577-85.
 43. Weber M, Neutel JM, Smith DHG. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. *J Am Coll Cardiol* 2001;37:169-74.
 44. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. *Lancet* 2000;356:930-3.